Literature DB >> 10535881

A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis.

M M Kaplan1, C Schmid, D Provenzale, A Sharma, G Dickstein, A McKusick.   

Abstract

BACKGROUND & AIMS: The aim of this study was to determine if colchicine or methotrexate improves blood test results, symptoms, and/or liver histology in patients with primary biliary cirrhosis.
METHODS: Patients with histologically confirmed primary biliary cirrhosis whose serum alkaline phosphatase (ALP) levels were at least 2 times above normal and who were not yet candidates for liver transplantation received colchicine or methotrexate and were followed up for 2 years.
RESULTS: In patients receiving colchicine (n = 43), mean pruritus score decreased from 1.63 to 1.12 (P = 0.04), ALP level from 494 to 355 U/L (P < 0.0001), and alanine aminotransferase (ALT) level from 79 to 61 U/L (P < 0.0001). In patients receiving methotrexate (n = 42), pruritus score decreased from 1.25 to 0.44 (P = 0.0001), ALP from 478 to 235 U/L (P < 0.0001), and ALT from 96 to 61 U/L (P = 0.0001). Methotrexate but not colchicine significantly improved liver histology (P = 0.005) and serum immunoglobulin G levels (P = 0.0002). Methotrexate improved most blood test results more than colchicine. Serum bilirubin levels increased slightly with each drug, and albumin levels decreased slightly.
CONCLUSIONS: Both colchicine and methotrexate improved biochemical test results and symptoms in primary biliary cirrhosis, but the response to methotrexate was greater.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10535881     DOI: 10.1016/s0016-5085(99)70403-8

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  10 in total

Review 1.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

2.  Current status of therapy in autoimmune liver disease.

Authors:  Gideon M Hirschfield; Nadya Al-Harthi; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

Review 3.  Advances in pharmacotherapy for primary biliary cirrhosis.

Authors:  Hani S Mousa; Ana Lleo; Pietro Invernizzi; Christopher L Bowlus; Merril Eric Gershwin
Journal:  Expert Opin Pharmacother       Date:  2014-12-29       Impact factor: 3.889

Review 4.  Options for treatment of primary biliary cirrhosis.

Authors:  Ye H Oo; James Neuberger
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience.

Authors:  S Ian Gan; Mariana de Jongh; Marshall M Kaplan
Journal:  Dig Dis Sci       Date:  2008-12-12       Impact factor: 3.199

Review 6.  Clinical features and management of primary biliary cirrhosis.

Authors:  Andrea Crosignani; Pier-Maria Battezzati; Pietro Invernizzi; Carlo Selmi; Elena Prina; Mauro Podda
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

Review 7.  Bile formation and secretion.

Authors:  James L Boyer
Journal:  Compr Physiol       Date:  2013-07       Impact factor: 9.090

Review 8.  Colchicine for prevention of cardiovascular events.

Authors:  Lars G Hemkens; Hannah Ewald; Viktoria L Gloy; Armon Arpagaus; Kelechi K Olu; Mark Nidorf; Dominik Glinz; Alain J Nordmann; Matthias Briel
Journal:  Cochrane Database Syst Rev       Date:  2016-01-27

9.  Fenofibrate for patients with asymptomatic primary biliary cirrhosis.

Authors:  Kazufumi Dohmen; Toshihiko Mizuta; Makoto Nakamuta; Naoya Shimohashi; Hiromi Ishibashi; Kyosuke Yamamoto
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

Review 10.  Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis.

Authors:  Francesca Saffioti; Kurinchi Selvan Gurusamy; Leonardo Henry Eusebi; Emmanuel Tsochatzis; Brian R Davidson; Douglas Thorburn
Journal:  Cochrane Database Syst Rev       Date:  2017-03-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.